Kusamura, M. Guaglio, M. Deraco Dario Baratti Doctor of Medicine, Peritoneal Malignancy Program, Fondazione IRCCS Istituto Nazionale Tumori, via Venezian, 1 20133 Milano, Italy. <...> Shigeki Kusamura Doctor of Philosophy, Peritoneal Malignancy Program, Fondazione IRCCS Istituto Nazionale Tumori, via Venezian, 1 20133 Milano, Italy. <...> Marcello Deraco Doctor of Medicine, Peritoneal Malignancy Program, Fondazione IRCCS Istituto Nazionale Tumori, via Venezian, 1 20133 Milano, Italy. <...> Only recently, cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has resulted in survival improvements. <...> From these series, the weighted median overall survival was 31,6 months (range 16–51). <...> The recent literature suggests that CRS/HIPEC is gaining acceptance as standard of care for selected CRC-PM patients. <...> Refinement of selection criteria, and rationalization of comprehensive systemic and local-regional management is ongoing. <...> Prevention and early treatment of PM are new and promising options. <...> Keywords: colorectal cancer, peritoneal metastasis, cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, HIPEC, liver metastasis. 10 Т. 18, №С-1 – 2017 D. Baratti, Sh. <...> Kusamura, M. Guaglio, M. Deraco Introduction systemic chemotherapy (sCT), and targeted agents, have significantly improved patient prognosis. <...> The use of surgery and local-regional therapies to treat metastatic tumor regionally confined to specific organs (such as liver or lung) has resulted in further improvements [2]. <...> Peritoneal metastases (PM) from CRC has been C traditionally regarded as end-stage disease only amenable to palliative sCT, or supportive care [3]. <...> In recent years, better knowledge of the natural history has evolved into the current understanding of PM as a local-regional disease. <...> Despite a randomized trial, and a growing body of retrospective data suggesting survival benefit over historical non-randomized controls [5–6], criticism still centers on the scarcity of high-quality controlled studies, high rates of life-threatening complications, and lack of standardization of treatment protocols [3]. <...> The peritoneum was the second most common single site of metastasis, after the liver [8–9]. <...> Treatment by systemic chemotherapy There are poor literature data on sCT in CRC-PM patients <...>